Patents by Inventor Didier Roche

Didier Roche has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10654818
    Abstract: The invention relates to furane derivatives of formula (I) as inhibitors of ATAD2, a process for their preparation and use thereof.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: May 19, 2020
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Markus Berger, Jan Hübner, Antonius Ter Laak, Matyas Gorjanacz, Amaury Ernesto Fernandez-Montalvan, Vincent Rodeschini, Didier Roche
  • Patent number: 10386414
    Abstract: A device may include a control circuit configured to place, after a normal mode operation of N flip-flops, the N flip-flops in a test mode in which the test input of the first flip-flop of the chain is intended to receive a first sequence of test bits A memory may be configured to store a sequence of N values delivered by the test output of the last flip-flop of the chain. The control circuit may be configured to deliver, at the test input of the first flip-flop of the chain, the sequence of N stored values to restore the state of the N flip-flops before their placement in the test mode.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: August 20, 2019
    Assignees: STMICROELECTRONICS (CROLLES 2) SAS, STMICROELECTRONICS (GRENOBLE 2) SAS
    Inventors: Jean-Marc Daveau, Philippe Roche, Didier Fuin
  • Publication number: 20190218196
    Abstract: The invention relates to furane derivatives of formula (I) as inhibitors of ATAD2, a process for their preparation and use thereof.
    Type: Application
    Filed: November 30, 2016
    Publication date: July 18, 2019
    Inventors: Markus BERGER, Jan HÜBNER, Antonius TER LAAK, Matyas GORJANACZ, Amaury Ernesto FERNANDEZ-MONTALVAN, Vincent RODESCHINI, Didier ROCHE
  • Patent number: 10071108
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
    Type: Grant
    Filed: February 19, 2018
    Date of Patent: September 11, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE CLAUDE BERNARD—LYON 1, ENS—ECOLE NORMALE SUPÉRIEURE DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), EDELRIS, POXEL
    Inventors: Patrice Andre, Vincent Lotteau, Pauline Radreau, Marine Gilardone, Amaury Patin, Didier Roche, Daniel Cravo, Sophie Hallakou-Bozec
  • Publication number: 20180169115
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
    Type: Application
    Filed: February 19, 2018
    Publication date: June 21, 2018
    Inventors: PATRICE ANDRE, VINCENT LOTTEAU, PAULINE RADREAU, MARINE GILARDONE, AMAURY PATIN, DIDIER ROCHE, DANIEL CRAVO, SOPHIE HALLAKOU-BOZEC
  • Patent number: 9895380
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: February 20, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ CLAUDE BERNARD—LYON 1, ENS—ECOLE NORMALE SUPÉRIEURE DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), EDELRIS, POXEL
    Inventors: Patrice Andre, Vincent Lotteau, Pauline Radreau, Marine Gilardone, Amaury Patin, Didier Roche, Daniel Cravo, Sophie Hallakou-Bozec
  • Publication number: 20170283426
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.
    Type: Application
    Filed: March 30, 2017
    Publication date: October 5, 2017
    Inventors: Catherine JORAND-LEBRUN, Theresa L. JOHNSON, Ulrich GRAEDLER, Xuliang JIANG, Didier ROCHE, Hugues LEMOINE, Marine GILARDONE
  • Publication number: 20170283425
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.
    Type: Application
    Filed: March 30, 2017
    Publication date: October 5, 2017
    Inventors: Catherine JORAND-LEBRUN, Theresa L. JOHNSON, Ulrich GRAEDLER, Xuliang JIANG, Didier ROCHE, Hugues LEMOINE, Marine GILARDONE
  • Publication number: 20160220586
    Abstract: The invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
    Type: Application
    Filed: September 10, 2014
    Publication date: August 4, 2016
    Inventors: PATRICE ANDRE, VINCENT LOTTEAU, PAULINE RADREAU, MARINE GILARDONE, AMAURY PATIN, DIDIER ROCHE, DANIEL CRAVO, SOPHIE HALLAKOU-BOZEC
  • Patent number: 8765728
    Abstract: The present invention relates to compounds of formula (I) compositions, in particular pharmaceutical compositions, and medicaments comprising at least one compound of formula (I). The invention also relates to the use of such a compound for manufacturing a medicament. In particular the medicament and the pharmaceutical composition are intended to treat diseases linked with insulin regulation problems, such as diabetes. This invention aims also to methods for treating or preventing such diseases.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: July 1, 2014
    Assignee: MelliTech
    Inventors: Didier Roche, Fabrice Chimienti, Martin Ohsten
  • Patent number: 8586577
    Abstract: The present invention relates to diazepane-acetamide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: November 19, 2013
    Assignee: Merck Patent GmbH
    Inventors: Denis Carniato, Caroline Leriche, Didier Roche, Christine Charon, Liliane Doare
  • Patent number: 8575161
    Abstract: The present invention relates to compounds of formula (I) wherein the substituents are as defined in the claims, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention and/or amelioration of one or more symptoms of disease or disorders related to the activity of FXR. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I).
    Type: Grant
    Filed: March 30, 2009
    Date of Patent: November 5, 2013
    Assignee: Merck Patent GmbH
    Inventors: Didier Roche, Gisèle Mautino, Ingo Kober, Francis Contard, Serge Christmann-Franck, Saumitra Sengupta, Ramesh Sistla, Gummadi Venkateshwar Rao
  • Patent number: 8546575
    Abstract: The present invention relates to NIP thiazole derivatives of formula (I) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11-?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: October 1, 2013
    Assignee: Merck Patent GmbH
    Inventors: Caroline Leriche, Denis Carniato, Didier Roche, Christine Charon, Liliane Doare
  • Patent number: 8486964
    Abstract: The present invention relates to fused pyrrolidino-cyclopropane derivatives according to formulae (I) to (IV) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11-?-HSD-1) and the use of such compounds for the treatment and/or prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: August 5, 2009
    Date of Patent: July 16, 2013
    Assignee: Merck Patent GmbH
    Inventors: Eric Valeur, Franck Lepifre, Didier Roche, Denis Carniato, Serge Christmann-Franck, Fabien Schmidlin
  • Patent number: 8470849
    Abstract: The present invention relates to 7-azaindole derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: June 25, 2013
    Assignee: Merck Patent GmbH
    Inventors: Denis Carniato, Didier Roche, Sophie Hallakou-Bozec, Melanie Schultz
  • Patent number: 8466200
    Abstract: The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: June 18, 2013
    Assignee: Merck Patent GmbH
    Inventors: Denis Carniato, Christine Charon, Johannes Gleitz, Didier Roche, Bjoern Hock
  • Publication number: 20120283247
    Abstract: The present invention relates to diazepane-acetamide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Application
    Filed: July 17, 2012
    Publication date: November 8, 2012
    Applicant: MERCK PATENT GMBH
    Inventors: Denis CARNIATO, Caroline LERICHE, Didier ROCHE, Christine CHARON, Liliane DOARE
  • Publication number: 20120225892
    Abstract: The present invention relates to compounds of formula (I) compositions, in particular pharmaceutical compositions, and medicaments comprising at least one compound of formula (I). The invention also relates to the use of such a compound for manufacturing a medicament. In particular the medicament and the pharmaceutical composition are intended to treat diseases linked with insulin regulation problems, such as diabetes. This invention aims also to methods for treating or preventing such diseases.
    Type: Application
    Filed: November 16, 2010
    Publication date: September 6, 2012
    Applicant: MELLITECH
    Inventors: Didier Roche, Fabrice Chimienti, Martin Ohsten
  • Patent number: 8242107
    Abstract: The present invention relates to diazepane-acetamide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: October 5, 2007
    Date of Patent: August 14, 2012
    Assignee: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Denis Carniato, Caroline Leriche, Didier Roche, Christine Charon, Liliane Doare
  • Publication number: 20120172396
    Abstract: The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Application
    Filed: February 7, 2012
    Publication date: July 5, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Denis CARNIATO, Christine CHARON, Johannes GLEITZ, Didier ROCHE, Bjoern HOCK